FORTIS INC./ CA3495531079 /
| 15/11/2024 16:57:02 | Var. -0.50 | Volume | Denaro22:00:00 | Lettera22:00:00 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
|---|---|---|---|---|---|---|---|
| 41.72EUR | -1.18% | 662 Fatturato: 27,671.28 |
41.87Quantità in denaro: 119 | 42.03Quantità in lettera: 118 | 20.58 bill.EUR | - | - |
GlobeNewswire
06/08
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
23/07
Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
02/07
Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
18/06
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire
10/06
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
23/05
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire
15/05
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
24/04
Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire
24/04
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire
23/04
Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire
03/04
Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire
02/04
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire
28/03
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
19/03
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
